MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

Rhea-AI Summary

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharma company developing precision peptide therapies for endocrine and metabolic disorders, will present at the Jefferies 2026 Global Healthcare Conference in New York City.

The company’s leadership will present on June 3, 2026, with a live webcast and 90-day replay available.

News Market Reaction – MBX

-0.31%

-0.31% Session close to close

In the May 26 session, MBX declined 0.31%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights MBX’s participation at a major healthcare conference, offering another ...

Analysis

This announcement highlights MBX’s participation at a major healthcare conference, offering another forum to showcase its endocrine and obesity pipeline and strategy. It follows recent clinical and financial updates that emphasized cash of $440.0M funding operations into 2029 and progress toward late-stage trials. With an effective S-3 shelf permitting up to $250,000,000 of common stock sales and recent insider activity disclosed, investors may watch for any financing or strategic signals shared during the presentation.

Key Figures

Conference date: June 3, 2026 Presentation start time: 8:10 a.m. ET Presentation end time: 8:40 a.m. ET +1 more

4 metrics

Conference date June 3, 2026 Jefferies 2026 Global Healthcare Conference presentation date

Presentation start time 8:10 a.m. ET Start time of Jefferies conference presentation

Presentation end time 8:40 a.m. ET End time of Jefferies conference presentation

Webcast archive period approximately 90 days Duration replay remains available on company website

Historical Context

5 past events · Latest: May 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	Clinical data update	Positive	-2.2%	Initial Phase 1 MBX 4291 obesity data and portfolio expansion plans.
May 07	Earnings and pipeline	Positive	+8.1%	Q1 2026 results, $440M cash runway into 2029, canvuparatide progress.
May 07	Management change	Positive	+8.1%	Appointment of Chief Commercial Officer and related equity inducement grant.
Apr 23	Investor event	Neutral	-0.6%	Announcement of Obesity Day to discuss obesity portfolio and PEP platform.
Mar 12	Earnings and pipeline	Neutral	-3.4%	FY 2025 results, $459.1M cash, ongoing clinical advancement across programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has produced mixed reactions: positive clinical and earnings updates saw both gains and pullbacks, suggesting investors respond selectively to catalysts.

Recent Company History

Over recent months, MBX has highlighted strong cash resources and advancing endocrine and obesity programs. Q4 2025 and Q1 2026 updates showed cash of $459.1M and $440.0M funding operations into 2029, alongside a Q1 net loss of $23.5M. Clinical news included Phase 1 obesity data for MBX 4291 with planned further readouts, and progress toward Phase 3 for once-weekly canvuparatide. Announcements of an Obesity Day event and a new Chief Commercial Officer underscored growing commercial and portfolio focus, to which the stock has reacted both positively and negatively across events.

Key Terms

webcast

1 terms

webcast technical

"The live webcast can be accessed under the Events section of the MBX Biosciences website"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at the Jefferies 2026 Global Healthcare Conference in New York City.

The presentation will take place on Wednesday, June 3, 2026, from 8:10 a.m. to 8:40 a.m. ET.

The live webcast can be accessed under the Events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. A replay of the webcast will be accessible approximately two hours following the conclusion of the presentation and will remain archived on the Company’s website for approximately 90 days.

About MBX Biosciences

MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the company website at www.mbxbio.com and follow it on LinkedIn.

Media Contact:

George Shea
We. Communications
gshea@wecommunications.com
(937) 232-4889

Investor Contact:

Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

FAQ

When will MBX Biosciences (MBX) present at the Jefferies 2026 Global Healthcare Conference?

MBX Biosciences will present on Wednesday, June 3, 2026, from 8:10 a.m. to 8:40 a.m. ET. According to MBX Biosciences, the session features its President and CEO and its Chief Medical Officer.

How can investors watch the MBX Biosciences (MBX) presentation at the Jefferies 2026 conference?

Investors can watch the MBX Biosciences presentation via a live webcast under the Events section of its investor website. According to MBX Biosciences, a replay will be posted about two hours after the session.

Where will the MBX Biosciences (MBX) Jefferies 2026 webcast replay be available and for how long?

The replay will be available on the MBX Biosciences website in the Events section. According to MBX Biosciences, the archived webcast will remain accessible for approximately 90 days after the presentation concludes.

Who will represent MBX Biosciences (MBX) at the Jefferies 2026 Global Healthcare Conference?

President and CEO Kent Hawryluk and Chief Medical Officer Sam Azoulay, M.D., will represent MBX Biosciences. According to MBX Biosciences, they will present the company’s story and clinical-stage focus on precision peptide therapies.

What does MBX Biosciences (MBX) focus on as a clinical-stage biopharmaceutical company?

MBX Biosciences focuses on discovering, developing and commercializing novel precision peptide therapies. According to MBX Biosciences, its pipeline targets endocrine and metabolic disorders, positioning the company within a specialized segment of the biopharmaceutical sector.